Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds
Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, ...
Weight loss drugs could help with alcohol, opioid addiction, study says
Drugs​ like Mounjaro and Ozempic, which many use for weight loss,​​ may also help patients suffering from addiction, ...
Unemployed Brits will receive free Ozempic-style weight-loss shots to help them get jobs
Britain has apparently found a solution to the global unemployment crisis: Weight loss shots. Prime Minister Keir Starmer ...
CBS19 News10h
Weight-Loss Meds Like Wegovy Could Battle Alcoholism
THURSDAY, Oct. 17, 2024 (HealthDay News) -- Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear ...
ConsumerAffairs22h
Compounding pharmacies can keep making Mounjaro and Zepbound copies
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Health.com1d
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
Mounjaro is more effective for weight loss than Ozempic—how does it work? And why does it cost so much?
,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...
Could weight-loss drugs boost the economy?
Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year ...
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
All of this means Lilly investors shouldn't panic. Even in the "worst case," Lilly's weight loss drugs have driven major revenue growth, and this is likely to continue -- whether compounders halt ...